trial

Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

NCTId NCT00207064
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 46 (actual)
Sponsored by Birte Glenthoj
Primary completion 2008-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
46 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Factorial
Masking
None
Start
2004-04
Primary completion
2008-09
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

Birte GlenthojLead Sponsor
Rigshospitalet, DenmarkCollaborator
Copenhagen University Hospital, HvidovreCollaborator
Glostrup University Hospital, CopenhagenCollaborator
The Danish Medical Research CouncilCollaborator
Copenhagen Hospital CorporationCollaborator
University of CopenhagenCollaborator
AstraZenecaCollaborator

Investigators

1
Birte Glenthoj, MD, DMSc.Study Director

Sites

3 total
Copenhagen, DenmarkGlostrup Municipality, DenmarkHvidovre, Denmark

Facts & assertions

4 sourced
Enrollment
46
Phase
NA
Primary Completion Date
2008-09
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
Birte Glenthoj
company
collaborator
Rigshospitalet, Denmark
company
Copenhagen University Hospital, Hvidovre
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Birte Glenthoj, MD, DMSc.
person